Meropenem Qilu

Meropenem, the active ingredient in Meropenem Qilu, is a carbapenem presented as a sterile powder for reconstitution for intravenous use. It treats a broad range of serious bacterial infections in hospitalized patients, including intra‑abdominal infections, urinary tract infections, meningitis, pneumonia, and sepsis. GNH USA supplies Meropenem Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used for severe infections caused by susceptible bacteria. - Complicated intra‑abdominal infections: provides rapid bacterial clearance in severe abdominal sepsis. - Complicated urinary tract infections: eradicates resistant uropathogens in hospital‑acquired UTIs. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat meningitic pathogens. - Hospital‑acquired pneumonia: effective against multidrug‑resistant organisms causing ventilator‑associated pneumonia. - Sepsis: offers timely bactericidal activity in systemic infections.

Adverse reactions may occur with meropenem therapy.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: occasional feeling of queasiness. - Headache: transient cranial discomfort. - Injection site erythema: localized redness at the IV site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Severe allergic reactions: anaphylaxis, urticaria, or angioedema. - Clostridioides difficile colitis: antibiotic‑associated colitis presenting with watery diarrhea.

Use meropenem only under medical supervision, considering patient‑specific factors. - Renal function: adjust dose in patients with impaired kidney function. - CNS disorders: monitor for neurotoxicity, particularly seizures. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Drug hypersensitivity: avoid in individuals with known carbapenem or beta‑lactam allergy. - Concomitant valproic acid: monitor serum levels as meropenem may reduce them. Store at ambient temperature: keep in original container, protect from moisture and light.

Meropenem may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Valproic acid: may markedly decrease valproate concentrations, risking seizure breakthrough. - Probenecid: can increase meropenem plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxicity; monitor renal function. - Loop diuretics: potential additive ototoxicity when used with aminoglycosides. - Anticoagulants (warfarin): monitor INR as infection may alter coagulation status.